title: Effect of anemia on hepatotoxicity of HAART in HIV patients in Benin city.
abstract: BACKGROUND
  Hepatotoxicity is a relevant adverse effect of highly active antiretroviral Treatment owing to its frequency, and it can cause interruption of therapy, hepatitis, and death. There is dearth of information on hepatotoxicity arising from highly active antiretroviral therapy (HAART) in anemic patients. Anemia is the most common symptom in human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome. We studied the effect of anemia on hepatotoxicity in HIV patients who were about to start HAART, attending clinic, or in the medical wards.
  
  
  METHODS
  This was a prospective study in which patients were recruited consecutively and followed up for 24 weeks.
  
  
  RESULTS
  In all, 84 patients were recruited and 42 were enrolled as controls. The mean ages of the cases and controls were 35.2±9.9 and 35.5±9.0 years, respectively. The age range of the cases was 18-68 years with a median age of 31.5 years, whereas the mean age of the controls was 20-57 years with a median age of 33.5 years. There was no difference (t=0.197, df=124, and P=0.844). There were 61 females (72.6%) and 23 males (27.4%) in the cases, whereas in the controls, there were 34 females (81.0%) and 8 males (19.0%). Among the cases, 30 (35.7%) were anemic, while 54 (64.3%) were not anemic. Six (20%) of the anemic patients had hepatotoxicity, and 9 (16.7%) of the patients with normal packed cell volume had hepatotoxicity. Among the controls, all 42 (100%) patients had normal packed cell volume. Four (9.5%) of the patients had hepatotoxicity. There was no association between hepatotoxicity and anemia (χ(2) =3.243, df=2, P=0.198).
  
  
  CONCLUSIONS
  Anemia did not affect hepatotoxicity of HAART in this study.
authors.affiliation: Department of Medicine, Gastroenterology Unit, University of Benin Teaching Hospital, Benin City, Edo State, Nigeria.
authors.forename: Rose A
authors.initials: RA
authors.lastname: Ugiagbe
authors.forename: Emeka U
authors.initials: EU
authors.lastname: Eze
references.citation: AIDS Rev. 2003 Jan-Mar;5(1):36-43
references.pmid: 12875106
references.citation: JAMA. 2000 Jan 5;283(1):74-80
references.pmid: 10632283
references.citation: Lancet. 2003 Nov 22;362(9397):1708-13
references.pmid: 14643119
references.citation: Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S90-7
references.pmid: 14986280
references.citation: Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S65-72
references.pmid: 14986277
references.citation: Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S73-9
references.pmid: 14986278
references.citation: J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S34-9
references.pmid: 14562856
references.citation: AIDS. 2003 May 2;17(7):987-99
references.pmid: 12700448
references.citation: Baillieres Best Pract Res Clin Haematol. 2000 Jun;13(2):215-30
references.pmid: 10942622
references.citation: Am J Med. 2004 Apr 5;116 Suppl 7A:27S-43S
references.pmid: 15050884
references.citation: J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):340-5
references.pmid: 11917237
references.citation: J Antimicrob Chemother. 2007 Mar;59(3):342-6
references.pmid: 17255142
references.citation: J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):426-31
references.pmid: 11511818
references.citation: J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S21-33
references.pmid: 14562855
references.citation: J Infect Dis. 2002 Jul 1;186(1):23-31
references.pmid: 12089658
references.citation: Lancet. 2004 Apr 17;363(9417):1253-63
references.pmid: 15094269